HuGE Literature Finder
|
||
Records 1-16
|
Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Antiviral therapy 2015 20 (3): 297-306. Gengiah Tanuja N, Botha Julia H, Yende-Zuma Nonhlanhla, Naidoo Kogieleum, Abdool Karim Salim |
|
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
The Journal of antimicrobial chemotherapy 2014 Aug 69 (8): 2175-82. Haas David W, Kwara Awewura, Richardson Danielle M, Baker Paxton, Papageorgiou Ioannis, Acosta Edward P, Morse Gene D, Court Michael |
|
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
The Journal of antimicrobial chemotherapy 2014 Feb 69 (2): 491-9. Sarfo Fred S, Zhang Yuan, Egan Deirdre, Tetteh Lambert A, Phillips Richard, Bedu-Addo George, Sarfo Maame Anima, Khoo Saye, Owen Andrew, Chadwick David |
|
Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
Therapeutic drug monitoring 2013 Feb 35 (1): 78-83. Cortes Claudia P, Siccardi Marco, Chaikan Ammara, Owen Andrew, Zhang Guijun, la Porte Charles J |
|
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
PloS one 2013 8 (7): e67946. Ngaimisi Eliford, Habtewold Abiy, Minzi Omary, Makonnen Eyasu, Mugusi Sabina, Amogne Wondwossen, Yimer Getnet, Riedel Klaus-Dieter, Janabi Mohammed, Aderaye Getachew, Mugusi Ferdinand, Bertilsson Leif, Aklillu Eleni, Burhenne Juerg |
|
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.
The pharmacogenomics journal 2012 Dec 12 (6): 499-506. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli W E, Burhenne J, Aderaye G, Lindquist L, Aklillu |
|
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
The pharmacogenomics journal 2012 Oct . Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E |
|
Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.
Pharmacogenomics 2012 Apr 13 (5): 555-70. Li Jing, Menard Vincent, Benish Rebekah L, Jurevic Richard J, Guillemette Chantal, Stoneking Mark, Zimmerman Peter A, Mehlotra Rajeev |
|
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
European journal of clinical pharmacology 2012 Mar 68 (3): 267-71. Maimbo Milimo, Kiyotani Kazuma, Mushiroda Taisei, Masimirembwa Collen, Nakamura Yusu |
|
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
Antimicrobial agents and chemotherapy 2011 Nov 55 (11): 5314-24. Sánchez Almudena, Cabrera Salvador, Santos Dolores, Valverde M Paz, Fuertes Aurelio, Domínguez-Gil Alfonso, García María J, |
|
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
The Journal of antimicrobial chemotherapy 2011 Oct 66 (10): 2350-61. Habtewold Abiy, Amogne Wondwossen, Makonnen Eyasu, Yimer Getnet, Riedel Klaus-Dieter, Ueda Nobuhisa, Worku Alemayehu, Haefeli Walter Emil, Lindquist Lars, Aderaye Getachew, Burhenne Jürgen, Aklillu Ele |
|
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success.
The Journal of infectious diseases 2011 Jul 204 (2): 291-8. Mehlotra Rajeev K, Cheruvu Vinay K, Blood Zikursh Melinda J, Benish Rebekah L, Lederman Michael M, Salata Robert A, Gripshover Barbara, McComsey Grace A, Lisgaris Michelle V, Fulton Scott, Subauste Carlos S, Jurevic Richard J, Guillemette Chantal, Zimmerman Peter A, Rodriguez Benig |
|
Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis.
European journal of clinical pharmacology 2010 Nov 66 (11): 1119-30. Joy Melanie S, Boyette Tammy, Hu Yichun, Wang Jinzhao, La Mary, Hogan Susan L, Stewart Paul W, Falk Ronald J, Dooley Mary Anne, Smith Philip |
|
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Pharmacogenomics 2010 Sep 11 (9): 1223-34. Elens Laure, Vandercam Bernard, Yombi Jean-Cyr, Lison Dominique, Wallemacq Pierre, Haufroid Vince |
|
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
AIDS (London, England) 2009 Oct 23 (16): 2101-6. Kwara Awewura, Lartey Margaret, Sagoe Kwamena W C, Kenu Ernest, Court Michael |
|
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.
Journal of clinical pharmacology 2009 Sep 49 (9): 1079-90. Kwara Awewura, Lartey Margaret, Boamah Isaac, Rezk Naser L, Oliver-Commey Joseph, Kenu Ernest, Kashuba Angela D M, Court Michael |
- Page last reviewed:Jul 30, 2019
- Page last updated:Dec 5, 2019
- Content source: